New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
10:38 EDTGES, GLNG, RMTI, KORS, BIG, EXPR, GDP, INCY, CONN, ANFOptions with decreasing implied volatility
Options with decreasing implied volatility: GDP RMTI ANF EXPR GLNG CONN BIG GES INCY KORS
News For GDP;RMTI;ANF;EXPR;GLNG;CONN;BIG;GES;INCY;KORS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
February 2, 2016
06:56 EDTKORSMichael Kors reports Q3 EPS $1.59, consensus $1.46
Subscribe for More Information
February 1, 2016
14:32 EDTKORSNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Exxon Mobil (XOM), consensus 64c... Pfizer (PFE), consensus 52c... United Parcel Service (UPS), consensus $1.42... Dow Chemical (DOW), consensus 70c... Emerson Electric (EMR), consensus 51c... Archer-Daniels-Midland (ADM), consensus 66c... Baxter (BAX), consensus 32c... Sirius XM (SIRI), consensus 3c... Royal Caribbean Cruises (RCL), consensus 92c... Ally Financial (ALLY), consensus 51c... Michael Kors (KORS), consensus $1.46... ADT Corp. (ADT), consensus 46c.
13:41 EDTKORSMichael Kors February weekly 40.5 straddle priced for 9.3% movement into Q3
Subscribe for More Information
12:41 EDTKORSEarnings Watch: Analyst urges 'another look' at Michael Kors ahead of Q3 report
Subscribe for More Information
11:42 EDTKORSStocks with call strike movement; YHOO KORS
Subscribe for More Information
08:09 EDTKORSOptions expected to be active
Options expected to be active: GOOGL GOOG YHOO UPS KORS UPS BAX RCL CCL PFE AET D STR DWA CMG ABT SYK.
07:28 EDTKORSJefferies tells investors to take another look at Michael Kors
Subscribe for More Information
January 29, 2016
11:54 EDTGESGuess to implement program to eliminate angora fiber
The company noted, "During 2015, while developing our sustainability practices and publishing our first sustainability report, GUESS evaluated our practices related to the use of angora fibers. As a result of this process, GUESS is implementing a program to eliminate angora fiber from our future collections available in retail stores worldwide." GUESS CEO, Victor Herrero stated, "While in the past, GUESS has worked to ensure the minimal amount of angora used was ethically sourced, we feel the decision to eliminate angora moving forward is just the right thing to do."
11:27 EDTGLNGBarrow, Hanley, Mewhinney & Strauss reports 5.99% passive stake in Golar LNG
10:05 EDTGESGuess says angora fiber 'should not be used' in production of any product
Guess?, Inc. announces that during 2015, while developing our sustainability practices and publishing its first sustainability report, it evaluated our policy related to the use of angora fiber. The company comments: "Effective immediately, angora fiber should not be used in the production of any product going forward or contained in any private label products. This pertains to promotional items as well."
09:03 EDTKORSMichael Kors volatility elevated into Q3 and outlook
Michael Kors February weekly call option implied volatility is at 83, February is at 55, March is at 45; compared to its 52-week range of 23 to 58, suggesting large near term price movement into the expected release of Q3 results on February 2.
January 28, 2016
11:33 EDTINCYOptions with increasing call volume
Subscribe for More Information
10:13 EDTGLNGOptions with decreasing implied volatility
Subscribe for More Information
08:14 EDTINCYIncyte selloff brings long-term buying opportunity, says Jefferies
Subscribe for More Information
08:08 EDTINCYIncyte selloff a buying opportunity, says Leerink
Leerink analyst Michael Schmidt recommends using today's pullback in shares of Incyte after the company announced its decision to stop one arm of its ongoing Phase II trial of ruxolitinib in metastatic colorectal cancer due to futility as a buying opportunity. The study is one of several ongoing trials to evaluate ruxolitinib in various solid tumor indications, the analyst points out. He says that while the news is disappointing, the stock's current valuation reflects very little if any value for ruxolitinib in solid tumor indications. Schmidt lowered his price target for Incyte shares to $118 from $135 and reiterates an Outperform rating on the name. The stock is down 13%, or $9.98, to $65.01 in pre-market trading.
07:43 EDTINCYIncyte weakness creates buying opportunity, says Oppenheimer
After Incyte announced that it would stop a Phase-2 study of Ruxolitinib plus regorafenib for R/R metastatic colorectal cancer and high-CRP patients due to insufficient efficacy, Oppenheimer says the data makes the drug's anti-inflammatory properties in solid tumors questionable. However, the firm did not previously include revenue from the drug outside of pancreatic cancer in its estimates. The firm keeps a $129 price target and Outperform rating on the shares.
January 27, 2016
19:30 EDTINCYOn The Fly: After Hours Movers
UP AFTER EARNINGS: Facebook (FB), up 11.4%... Mellanox (MLNX), up 6.4%... Paypal (PYPL), up 5%... Crown Castle (CCI), up 2.2%... Citrix (CTXS), up 2.4%... Las Vegas Sands (LVS), up 1%... SanDisk (SNDK), up 1%. ALSO HIGHER: Radius Health (RDUS), up 1.2% after announcing a clinical collaboration with Novartis (NVS)... LinkedIn (LNKD) is up 2.4%, Alphabet (GOOG, GOOGL) is up 2.2% and 2.6%, respectively, Netflix (NFLX) is up 1%, Amazon.com (AMZN) is up 2%, and Twitter (TWTR) is up marginally after Facebook reported quarterly results... MGM Resorts (MGM) is up 2.2% and Wynn Resorts (WYNN) is up 2.2%. DOWN AFTER EARNINGS: ServiceNow (NOW), down 16.5%... eBay (EBAY), down 12.8%... United Rentals (URI), down 9.7%... Juniper Networks (JNPR), down 9.6%... Silicon Graphics (SGI), down 9.1%... Discover Financial (DFS), down 7.4%... InvenSense (INVN), down 6.1%... Core Laboratories (CLB), down 4.3%... Vertex Pharmaceuticals (VRTX), down 1.1%. ALSO LOWER: Incyte (INCY), down 12.8% after announcing that it will halt the Phase 2 sub-study of ruxolitinib or placebo in combination with regorafenib after a planned interim analysis of the high CRP subgroup demonstrated that ruxolitinib plus regorafenib did not show a sufficient level of efficacy to warrant continuation.
16:45 EDTINCYIncyte to stop Phase 2 sub-study of ruxolitinib plus regorafenib
Subscribe for More Information
05:08 EDTGLNGStocks with implied volatility below IV index mean; AXP GLNG
Subscribe for More Information
January 25, 2016
17:33 EDTGLNGSchlumberger signs preliminary agreement for Fortuna FLNG project
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use